2685
Each subject was treated according to the following sequence: baseline; phase 1 (days 1-6): cisapride 10 mg 4 times/day; washout (days 7-13); phase 2 (days 14-44): fluoxetine 20 mg/day; and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52).
 Each subject: Subject; baseline; phase 1 (days 1-6): cisapride 10 mg 4 times/day; washout (days 7-13); phase 2 (days 14-44): fluoxetine 20 mg/day; and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52): Treatment; cisapride: Treatment.Drug; fluoxetine: Treatment.Drug; cisapride: Treatment.Drug; fluoxetine: Treatment.Drug; 10 mg: Treatment.Dosage; 20 mg/day: Treatment.Dosage; 10 mg: Treatment.Dosage; 20 mg/day: Treatment.Dosage; 4 times/day: Treatment.Freq; 4 times/day: Treatment.Freq; cisapride: Combination.Drug; fluoxetine: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 Each subject: Subject; baseline; phase 1 (days 1-6): cisapride 10 mg 4 times/day; washout (days 7-13); phase 2 (days 14-44): fluoxetine 20 mg/day; and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52): Treatment; cisapride: Treatment.Drug; fluoxetine: Treatment.Drug; cisapride: Treatment.Drug; fluoxetine: Treatment.Drug; 10 mg: Treatment.Dosage; 20 mg/day: Treatment.Dosage; 10 mg: Treatment.Dosage; 20 mg/day: Treatment.Dosage; 4 times/day: Treatment.Freq; 4 times/day: Treatment.Freq; cisapride: Combination.Drug; fluoxetine: Combination.Drug